AI Stock Memo: AZN - AstraZeneca - RankAlpha

AZN

Rating buyAI Memo

AstraZeneca

As of 2026-01-24/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-01-24 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

—

Key catalyst

FY2025 earnings release • 2026-02-10

Expected move: -47%

Biggest risk

Disappointing guidance, trial setbacks, or regulatory delays compress multiples and push shares toward the lower analyst range.

Invalidation

Break below $80 or thesis failure.

What would change my mind?

Positive late-stage readouts and a favorable FY2025 beat lead to multiple expansion and re-rating toward the upper analyst range within 12 months.

Research note

Recommendation

buy

Confidence

medium

As of

2026-01-24

Base target

$98

p=60%

Bull target

$124

p=25%

Bear target

$80

p=15%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Near-term capital-allocation update
Late-stage trial readouts / regulatory milestones
Positive late-stage readouts and a favorable FY2025 beat lead to multiple expansion and re-rating toward the upper analyst range within 12 months.

BearKey bullets

Late-stage clinical trial failure or delay
Macro/currency-driven demand weakness
Weaker-than-expected FY guidance or margin pressure

WatchKey bullets

FY2025 earnings release

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $98 (p=60%)

Bull/Bear spread: -33% / -57%

Vs latest close: Bull -33% · Base -47% · Bear -57%

Scenario probabilities

Bull Target: $124 (p=25%)Base Target: $98 (p=60%)Bear Target: $80 (p=15%)

Commentary

Consensus is mildly constructive with median targets near our base case; near-term focus is the FY2025 print, while longer-term sentiment hinges on late-stage pipeline outcomes.

As of 2026-01-24 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Positive late-stage readouts and a favorable FY2025 beat lead to multiple expansion and re-rating toward the upper analyst range within 12 months.

Bear Case

Disappointing guidance, trial setbacks, or regulatory delays compress multiples and push shares toward the lower analyst range.

Drivers

Scannable catalysts and supporting factors

Near-term capital-allocation update
Late-stage trial readouts / regulatory milestones

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-01-24Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$97.79

Range (USD)

$74.01 - $122.55

Count

Query: AstraZeneca PLC ADR (AZN) analyst consensus price target high low average

AstraZeneca PLC ADR Analyst Estimates - AZN - MarketWatch
Search result #1
Stock Price Targets. High, $122.55. Median, $104.37. Low, $74.01. Average, $102.26. Current Price, $90.54. Yearly Numbers. Estimates. AZN will report 2025 ...
Extracted: $122.55, $104.37, $74.01, $102.26, $90.54Open source
What is the current Price Target and Forecast for AstraZeneca (AZN)
Search result #2
The forecasts range from a low of $75.00 to a high of $108.50. The average price target represents an increase of 7.07% from the last closing price of $91.69.
Extracted: $75.00, $108.50, $91.69Open source
ASTRAZENECA PLC-SPONS ADR (AZN) Stock Analyst Ratings
Search result #3
33 analysts have analysed AZN and the average price target is 97.79 USD. This implies a price increase of 9.4% is expected in the next year compared to the ...
Extracted: $97.79Open source
Astrazeneca Plc (AZN) Stock Forecast, Price Targets and ... - TipRanks
Search result #4
The average price target is $103.00 with a high forecast of $108.00 and a low forecast of $95.00. The average price target represents a 12.34% change from the ...
Extracted: $103.00, $108.00, $95.00Open source
AstraZeneca PLC ADR Research & Ratings | AZN - Barron's
Search result #5
ConsensusBuyBuyBuy. Stock Price Target. High, $122.55. Low, $74.01. Average, $102.26. Current Price, $90.54. AZN will report FY 2025 earnings on 02/10/2026 ...
Extracted: $122.55, $74.01, $102.26, $90.54Open source
AZN | AstraZeneca PLC ADR Analyst Estimates & Ratings – WSJ
Search result #6
9.15 M. View Full Table. Stock Price Target AZN. High, $122.55. Median, $104.37. Low, $74.01. Average, $102.26. Current Price, $91.69. Overview · Research & ...
Extracted: $122.55, $104.37, $74.01, $102.26, $91.69Open source

Scenarios

Bull Target (Scenario probability)

$124 / p=25% prob

Base Target (Scenario probability)

$98 / p=60% prob

Bear Target (Scenario probability)

$80 / p=15% prob

Price $186 as of 2026-05-29

Nearest Scenario: Bull (∆ 33%)

Targets vs latest close: Bull -33% · Base -47% · Bear -57%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-02-10
FY2025 earnings release
Full-year 2025 results and guidance update; historically a primary re-pricing event for the stock.
Prob 80.00% • Move 6.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

Near-term capital-allocation update
2026-04-24
Potential buyback/dividend commentary or modest buyback tranche announcement that could support the share price.
Prob 30% • Move 3% • Priced-in 40%

Long-term Catalysts

Months to a year

Late-stage trial readouts / regulatory milestones
2027-01-24
Clinical or regulatory outcomes for late-stage assets that could drive material upside or downside over a longer horizon.
Prob 40% • Move 15% • Priced-in 20%

Risks

Late-stage clinical trial failure or delay
Macro/currency-driven demand weakness
Weaker-than-expected FY guidance or margin pressure

Peers

Symbol	Summary
PFE	Large diversified pharma; useful comparator for vaccines and established product performance.
JNJ	Broad healthcare franchise with comparable risk profile on safety and regulatory execution.
BMY	Oncology-focused peer with similar pipeline-driven growth dynamics and M&A activity.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: AstraZeneca PLC ADR (AZN) analyst consensus price target high low average
Analysis date: 2026-01-24